Monash Ivf Group Ltd - Asset Resilience Ratio
Monash Ivf Group Ltd (MVF) has an Asset Resilience Ratio of 1.60% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Monash Ivf Group Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Monash Ivf Group Ltd's Asset Resilience Ratio has changed over time. See Monash Ivf Group Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Monash Ivf Group Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Monash Ivf Group Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$8.14 Million | 1.6% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$8.14 Million | 1.60% |
Asset Resilience Insights
- Limited Liquidity: Monash Ivf Group Ltd maintains only 1.60% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Monash Ivf Group Ltd Industry Peers by Asset Resilience Ratio
Compare Monash Ivf Group Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
BGI Genomics Co Ltd
SHE:300676 |
Diagnostics & Research | 3.62% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.16% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Check-Cap Ltd
F:7CC |
Diagnostics & Research | 2.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
Annual Asset Resilience Ratio for Monash Ivf Group Ltd (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Monash Ivf Group Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.11% | AU$543.00K ≈ $384.21K |
AU$492.61 Million ≈ $348.55 Million |
-0.30pp |
| 2024-06-30 | 0.41% | AU$2.06 Million ≈ $1.46 Million |
AU$508.47 Million ≈ $359.77 Million |
-0.01pp |
| 2023-06-30 | 0.41% | AU$1.75 Million ≈ $1.23 Million |
AU$421.89 Million ≈ $298.52 Million |
+0.16pp |
| 2022-06-30 | 0.25% | AU$967.00K ≈ $684.21K |
AU$387.10 Million ≈ $273.90 Million |
-0.24pp |
| 2021-06-30 | 0.49% | AU$1.75 Million ≈ $1.24 Million |
AU$356.17 Million ≈ $252.02 Million |
-0.07pp |
| 2020-06-30 | 0.57% | AU$2.00 Million ≈ $1.42 Million |
AU$354.22 Million ≈ $250.64 Million |
+0.37pp |
| 2019-06-30 | 0.19% | AU$565.00K ≈ $399.77K |
AU$290.04 Million ≈ $205.22 Million |
+0.00pp |
| 2018-06-30 | 0.19% | AU$565.00K ≈ $399.77K |
AU$290.61 Million ≈ $205.63 Million |
0.00pp |
| 2017-06-30 | 0.20% | AU$565.00K ≈ $399.77K |
AU$287.25 Million ≈ $203.25 Million |
-- |
About Monash Ivf Group Ltd
Monash IVF Group Limited engages in the provision of assisted reproductive genetic and specialist women imaging services in Australia and Southeast Asia. It offers diagnostic obstetric, gynecological ultrasound, and fertility treatment services. The company also provides tertiary level prenatal diagnostic, ultrasound, and IVF treatment services. Monash IVF Group Limited was incorporated in 2014 a… Read more